Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$196.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Wright Reports
|
$460.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Block & Leviton LLP Investigates Abiomed Inc For Possible Violations Of Federal Securities Laws
Abiomed Inc announced that Block & Leviton LLP a Boston based law firm representing investors nationwide, is investigating possible securities law violations involving the Company following its disclosure of a Department of Justice investigation into marketing and labeling issues of its Impella 2.5 system.
Latest Developments for Abiomed Inc
- Abiomed Inc Issues FY 2014 Revenue Guidance In Line With Analysts' Estimates
- Abiomed Inc Reaffirms FY 2013 Revenue Guidance
- Abiomed Inc Announces That FDA 515i Reclassification Panel Recommends Class III Status for Temporary Ventricular Support Devices in Non-Roller Type Cardiopulmonary Bypass Blood Pumps Category
- Abiomed Inc Receives FDA IDE Approval For Use Of New Impella RP In Pivotal Clinical Study
Latest Key Developments in Advanced
- Varian Medical Systems Inc Receives FDA 510(k) Clearance Of Its Nexus DRF Digital X-Ray Imaging System
- Covidien PLC Announces Clinical Trial Data Showing Endoscopic Ablation Therapy Eliminates Precancerous Esophageal Tissue And Significantly Reduces Disease Progression
- Hologic Inc Receives FDA Approval For New Low-dose 3D Mammography (Breast Tomosynthesis) Solution For Breast Cancer Screening
- Echo Therapeutics Inc Announces Institutional Review Board (IRB) Approval For Clinical Trial Of Symphony CGM System
- Share this
- Link this
- Digg this
Follow Reuters